UE LifeSciences iBreastExam: Painless Early Detection of Breast Cancer in India
Early detection of breast cancer is critical for successful treatment, yet many women in India face significant barriers to getting screened. UE LifeSciences, a health technology company focused on Femtech, is changing the landscape of breast cancer screening with its innovative handheld device, the iBreastExam. This article explores how the iBreastExam offers a painless, accessible, and AI-enabled solution that prioritizes preventive healthcare and aims to reach millions of women across India.
Bridging the Gap in Breast Cancer Screening in India
India’s healthcare system faces challenges in early breast cancer detection, including a shortage of radiologists, limited access to mammography, and a high incidence of breast cancer among younger women with dense breast tissue. Mammography, while comprehensive, has limitations: it uses radiation and is usually recommended for women over 45. In contrast, younger women often remain unscreened despite significant risk.
The iBreastExam is designed as a first line of defense, complementing mammography by providing a safe, radiation-free screening method that is applicable across all age groups. It addresses the pressing need for a primary screening tool to identify women who need further diagnostic tests.
What is the iBreastExam and How Does It Work?
The iBreastExam is a portable, battery-operated device that uses capacitive sensor technology, similar to a smartphone touchscreen, to detect abnormalities in breast tissue. The entire process takes about 10 minutes and causes no pain or discomfort, unlike mammography that involves pressing breasts between cold metal plates.
This device is easy to use in diverse settings—clinical facilities, corporate offices, and even at home—with minimal infrastructure. Results are available immediately, thanks to an AI-enabled algorithm, which provides quick identification of potential issues and encourages timely follow-up with mammography or ultrasound.
Advantages Over Mammography
- Painless and Quick: The iBreastExam resembles the sensation of a stethoscope on the breast, eliminating the pain and anxiety associated with mammograms.
- Radiation-Free: Safe for all ages, including younger women who have dense breast tissue.
- Portable and Accessible: Battery-powered device suitable for rural areas and community outreach.
- Immediate Results: AI-driven analysis provides on-the-spot preliminary findings.
Driving Early Detection Through Community Networks
One of the biggest barriers to breast cancer screening in India is limited access due to a shortage of radiologists—there is just one radiologist per 100,000 people in India compared to one per 10,000 in the US. UE LifeSciences leverages community health workers, such as ASHA workers, to bring screening directly to women’s doorsteps. This approach builds trust and awareness within communities and makes screening more accessible and less intimidating.
Through partnerships with government bodies, hospitals, and NGOs, the iBreastExam has already conducted over two million screenings. Screening programs have been implemented in states like Goa and Maharashtra, with governments providing free treatment for women who test positive. This integration with existing healthcare infrastructure enables a seamless continuum from detection to treatment.
Case Study: Door-to-Door Screening in Gujarat
A recent initiative in Gujarat, in collaboration with local NGOs and funded by international foundations, involved trained operators conducting door-to-door screenings. Women with positive test results were referred to district hospitals for further examination. This model demonstrates how the iBreastExam can overcome geographic and socio-economic barriers to screening.
Incorporating AI for Efficient Screening and Follow-Up
The AI component of the iBreastExam plays a crucial role in improving screening efficiency. Rather than waiting for lab results, the AI analyzes data in real-time, enabling immediate counseling and referral for women with abnormal findings. This timely feedback increases the likelihood of follow-up care, which is critical for early-stage treatment success.
Expanding the Reach and Future Plans
While two million screenings is a significant milestone, UE LifeSciences aims to scale up its operations further. The goal is to make painless, early detection a standard of care available to every woman in India, reducing breast cancer mortality rates. By continuing to build partnerships across government and private sectors, leveraging grassroots health workers, and utilizing innovative technology, UE LifeSciences is positioned to transform breast cancer screening in India.
Collaborations with Private Hospitals
Besides government partnerships, UE LifeSciences works with private hospitals and corporate entities to facilitate convenient screenings for busy women. For example, corporate screening programs have been conducted for policewomen in Mumbai, with screenings taking place at their workplace to adapt to their schedules.
The Importance of Early Detection and Patient Stories
Breast cancer has a nearly 90% survival rate when detected early, highlighting the critical nature of timely screening. Personal stories from women who have benefited from the iBreastExam reinforce the life-saving potential of such technology. Early detection not only improves treatment outcomes but also minimizes side effects, allowing women to maintain a greater quality of life during and after treatment.
Conclusion
UE LifeSciences’ iBreastExam is revolutionizing breast cancer screening in India by offering a painless, rapid, and accessible option for early detection. Its AI-enabled technology, combined with community-based outreach, addresses the challenges of limited radiologists and mammography access, with the goal of reducing breast cancer mortality across the country. The future of breast cancer screening in India is bright, thanks to innovative solutions like the iBreastExam that empower women to prioritize their health with confidence.
